(ADCT) ADC Therapeutics S.A. Business Model Canvas Research

ADC Therapeutics S.A. has a strategic collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation that supports regional development, licensing, and commercialization in Japan and other Asian markets. The deal helps ADC Therapeutics extend reach beyond its Swiss base, while keeping local market execution with a Japan-based pharma partner; the public agreement did not disclose a deal value.

• Expands ADC Therapeutics beyond Switzerland
• Supports regional development and licensing
• Improves commercialization access in Asia
• Public deal value not disclosed

ADC Therapeutics S.A. lists Overland Pharmaceuticals and MedImmune Limited as key partners, giving it broader development support and faster reach into priority markets. These alliances sit inside its licensing network and help spread clinical, regulatory, and geographic execution risk.

• Supports external innovation and licensing
• Broadens geographic expansion options
• Shares development execution risk

ADC Therapeutics S.A.'s commercial execution centers on ZYNLONTA, its only marketed product, and connects the R&D pipeline to cash flow through market access, oncology promotion, and supply coordination. In 2024, ADC Therapeutics reported about $77 million in product revenue, so execution quality directly shapes growth and burn.

• ZYNLONTA drives current sales
• Market access supports reimbursement
• Promotion targets oncologists
• Supply coordination protects launches

ADC Therapeutics S.A. treats partnering and licensing as a core growth engine: it negotiates collaborations, licenses, and technology access deals to add science and reach without building every capability in-house. This matters because the Company’s model is still pipeline-led, with ZYNLONTA as its only approved product and revenue base still concentrated in a single asset.

• Uses external deals to extend R&D capacity.
• Reduces fixed cost versus full in-house build.
• Supports pipeline expansion and deal optionality.

ADC Therapeutics S.A. relies on one approved product, ZYNLONTA, and the license rights behind its antibody-drug conjugate platform to protect its differentiated payload chemistry and keep external innovation flowing in. That lowers development risk and helps defend pricing and market access.

• 1 approved product anchors the IP base
• Licenses protect core ADC technology
• IP access reduces R&D and launch risk

ADC Therapeutics relies on a clinical and commercial team with oncology development, regulatory, and sales skills to run trials, prepare filings, and support market launch. Headquartered in Epalinges, Switzerland, the company used this model in 2025 to advance ZYNLONTA, which generated $15.3 million in product revenue.

• Runs oncology trials
• Handles regulatory filings
• Drives market launch

ZYNLONTA's combination path with rituximab in second-line, transplant-ineligible DLBCL can lift response and widen use beyond monotherapy. In LOTIS-2, ZYNLONTA delivered a 48% overall response rate and 24% complete response rate, which supports pairing it with an anti-CD20 backbone in a crowded lymphoma market.

• Supports higher response depth.
• Expands transplant-ineligible use.
• Fits competitive DLBCL pathways.

Partner-enabled innovation lets ADC Therapeutics S.A. use licensed and co-developed science to speed up ADC work without building every platform in-house. That keeps the company focused on its core ADC pipeline and can lower upfront R&D spend, making the model more capital-efficient.

• Faster access to external science
• More focus on ADC development
• Lower capital intensity

Commercial oncology products like ADC Therapeutics S.A.'s need payer and hospital access work, because formulary placement, reimbursement, and utilization rules can decide whether a specialty cancer therapy gets used. In 2025, this meant proving budget impact, site-of-care fit, and real-world value fast, since delayed access can slow uptake and sales.

• Support formulary reviews
• Secure reimbursement terms
• Back prior-authorization decisions
• Work with hospital committees

Partner account management is key for ADC Therapeutics S.A. because collaboration deals need tight governance, from license terms to milestone checks and joint development plans. In 2025, the company still relied on one marketed product, ZYNLONTA, so protecting external partner value matters even more.

• Track licenses and milestone timing
• Align on joint development scope
• Keep partner obligations clear

ADC Therapeutics S.A. uses strategic partners as development and commercialization channels, which lets licensed partners extend its reach across regions and functions. This matters because the company relies on multiple collaboration agreements to move assets through trials and into market access without building every capability in-house.

• Expands geographic reach
• Supports development and sales
• Fits a multi-partner model

ADC Therapeutics S.A. uses medical congresses, peer-reviewed publications, and digital medical information to turn trial data into prescriber awareness. In oncology, where evidence drives prescribing behavior, these channels matter because they help move a study result from the lab into real-world adoption.

• Congress data builds first awareness
• Publications add clinical credibility
• Digital support keeps evidence accessible

Camidanlumab tesirine and ADCT-602 widen ADC Therapeutics S.A.'s reach beyond NHL into relapsed or refractory Hodgkin lymphoma and acute lymphoblastic leukemia, two high-need hematology settings with limited options. These programs target patients who often fail frontline therapy and can support a larger addressable pool in blood cancers.

• Relapsed or refractory Hodgkin lymphoma
• Acute lymphoblastic leukemia
• Expands beyond NHL

Biopharma partners are B2B customers that buy access to ADC Therapeutics S.A.'s antibody-drug conjugate technology, licenses, and co-development rights, creating non-product revenue through upfront fees, milestones, and royalties. In 2025, that partner income stayed a strategic add-on to ZYNLONTA sales, so deals matter for cash flow and pipeline reach.

• License access, not finished drugs
• Pay upfront, milestones, royalties
• Expand reach without building sales

ADC Therapeutics S.A. carries ongoing regulatory, compliance, and pharmacovigilance costs for its 1 marketed oncology product, ZYNLONTA, plus any pipeline programs. These costs scale with each active study because oncology needs tight safety tracking, quality control, and recurring filings.

• 1 product means constant post-marketing oversight.

• Each program adds submissions, audits, and safety reviews.

• Quality work is a fixed, multi-year cash drain.

ADC Therapeutics S.A. carries recurring licensing and IP costs for patent upkeep, collaboration fees, and protecting its ADC platform. The biggest risk is milestone payments under partner deals, which can trigger future cash outflows when programs hit set clinical or sales targets.

• Pay licenses and collaboration fees.
• Fund patent and IP upkeep.
• Plan for milestone cash outflows.

Royalties can pay ADC Therapeutics S.A. when partnered products reach market, so the company can earn long-life revenue with little added capital. That matters in a licensing-heavy model: one approved partner asset can keep paying for years while ADC Therapeutics avoids the full cost of launch and scale-up.

• Marketed partner assets can trigger royalty income.

• Low-capital revenue can last for years.

• Multiple licenses can diversify cash flow.

ADC Therapeutics S.A.’s future pipeline sales are still optional, not assured: camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, and ADCT-701 could all add new revenue streams if they reach approval. The upside is meaningful because, as of 2025, the Company still relied on one marketed product, so each win would broaden long-term commercial sales.

• Sales depend on approval success
• Multiple assets expand revenue optionality
• Pipeline can diversify beyond one product